1. Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report

   • Jianyong Wu
   • Yan Song
   • Jianghua Chen

   Review Article 16 September 2009 Pages: 1169 - 1174

2. A fenugreek seed extract selectively reduces spontaneous fat consumption in healthy volunteers

   • Hugues Chevassus
   • Nathalie Molinier
   • Pierre Petit

   Clinical Trial 07 October 2009 Pages: 1175 - 1178

   

3. Uptake of anthracyclines in vitro and in vivo in acute myeloid leukemia cells in relation to apoptosis and clinical response

   • Alex Bogason
   • Hasanuzzaman Bhuiyan
   • Sigurd Vitols

   Pharmacodynamics 10 October 2009 Pages: 1179 - 1186

   

4. Effects of CYP2C19 and CYP2C9 genotypes on pharmacokinetic variability of valproic acid in Chinese epileptic patients: nonlinear mixed-effect modeling

   • Dechun Jiang
   • Xiangrong Bai
   • Markus Müller

   Pharmacogenetics 16 September 2009 Pages: 1187 - 1193

   

5. Evidence for immunological (allergic) mechanisms in a subgroup of patients with phenprocoumon-induced liver disease

   • Reinhild Klein

   Pharmacokinetics and Disposition 30 July 2009 Pages: 1195 - 1201

   

6. Assessment of inter-individual variability in predicted phenytoin clearance

   • Thomas M. Polasek
   • Sebastian Polak
   • John O. Miners

   Pharmacokinetics and Disposition 01 August 2009 Pages: 1203 - 1210

   

7. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis

   • Adedigbo A. Fasanmade
   • Omoniyi J. Adedokun
   • Honghui Zhou

   Pharmacokinetics and Disposition Open access 16 September 2009 Pages: 1211 - 1228

   

8. Association between the use of anticholinergic antiparkinson drugs and safety and receptor drug-binding profiles of antipsychotic agents

   • Pål Gjerden
   • Lars Slørdal
   • Jørgen G. Bramness

   Pharmacoepidemiology and Prescription 31 July 2009 Pages: 1229 - 1235

9. Risk of digoxin intoxication caused by clarithromycin–digoxin interactions in heart failure patients: a population-based study

   • Agnes L. F. Chan
   • Meng-Ting Wang
   • Fu-Hsiung Tsai

   Pharmacoepidemiology and Prescription 05 August 2009 Pages: 1237 - 1243

   

10. Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson’s disease

    • Maurits E. L. Arbouw
    • Kris L. L. Movig
    • Henk-Jan Guchelaar

    Pharmacoepidemiology and Prescription Open access 08 August 2009 Pages: 1245 - 1251

    

11. Evidence of safety of chloral hydrate for prolonged sedation in PICU in a tertiary teaching hospital in southern Brazil

    • Jacqueline Kohut Martinbiancho
    • Paulo Roberto Antonacci Carvalho
    • Leila Beltrami Moreira

    Pharmacoepidemiology and Prescription 11 August 2009 Pages: 1253 - 1258

12. Montelukast use during pregnancy: a multicentre, prospective, comparative study of infant outcomes

    • Moumita Sarkar
    • Gideon Koren
    • Adrienne Einarson

    Pharmacoepidemiology and Prescription 26 August 2009 Pages: 1259 - 1264

13. Therapeutic efficacy of acenocoumarol in a warfarin-resistant patient with deep venous thrombosis: a case report

    • Srecko Marusic
    • Nives Gojo-Tomic
    • Nada Bozina

    Letter to the Editors 04 August 2009 Pages: 1265 - 1266

14. Individualised dosing of amikacin in neonates

    • Catherine M. T. Sherwin
    • Roland S. Broadbent
    • David M. Reith

    Letter to the Editors 05 August 2009 Pages: 1267 - 1268

15. Delirium, thrombocytopenia, insomnia, and mild liver damage associated with MAOI withdrawal

    • Alfredo Bellon
    • John H. Coverdale

    Letter to the Editors 05 August 2009 Pages: 1269 - 1270

16. Paroxetine may cause increase in carcinoebmryonic antigen (CEA)

    • Mehmet Emin Ceylan
    • Ahmet Turkcan
    • Urun Ozer

    Letter to the Editors 18 August 2009 Pages: 1271 - 1271